rrx-001,regorafenib
epicentrx,bayer
[]
#epicentrx announces presentation for phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of #rrx001 vs. #regorafenib in third/fourth line #colorectalcancer at the #ascogi23 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.